Ropeginterferon alfa-2b-njft (P1101) achieved durable hematologic responses in ET patients with a manageable safety profile, outperforming anagrelide in the SURPASS-ET trial. P1101 showed a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback